Drug Trial Radar · NCT06902519
Study of GS-0151 in Participants With Rheumatoid Arthritis
Last checked: Nov 20, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
65
Actual
Start
May 14, 2025
Primary completion
Mar 2027
Study completion Mar 2027
Sponsor
- Lead sponsor
- Gilead SciencesGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Mar 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to learn more about the study drug GS-0151. The study is done to find how safe, well-tolerated the drug is. This will also assess how the drug is absorbed, modified, distributed and cleared from the body (the pharmacokinetics (PK) of the drug), when given multiple times to participants with rheumatoid arthritis (RA). The primary objectives of this study is to assess the safety and tolerability of multiple ascending doses of GS-0151 in participants with RA and to characterize the PK of GS-0151 following multiple doses of GS-0151 in participants with RA.
Conditions
- Rheumatoid Arthritis
Interventions
GS-0151Drug
Administered for 12 weeks
PlaceboDrug
Administered for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort 1, 2 and 3: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Time frame: First dose up to 19 Weeks post end of treatment at Week 12
- Cohort 1, 2 and 3: Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesTime frame: First dose up to 19 Weeks post end of treatment at Week 12
- Cohorts 1, 2 and 3: Percentage of Participants Experiencing Serous Adverse Events (SAEs) and Adverse Events (AEs) Leading to Study DiscontinuationTime frame: First dose up to 19 Weeks post end of treatment at Week 12
- Cohort 1, 2 and 3: Serum AUCtau Following the Last Dose of GS-0151Time frame: Up to Week 12
- Cohorts 1, 2 and 3: Serum Cmax, Following the Last Dose of GS-0151Time frame: Up to Week 12
- Cohorts 1, 2 and 3: Serum Tmax Following the Last Dose of GS-0151Time frame: Up to Week 12
Locations
35 sites in 6 countries. Site status is shown where the registry gives one.
Pinnacle Research Group, LLC
Anniston, Alabama
University of California, San Diego
La Jolla, California
Stanford University School of Medicine
Palo Alto, California
Medvin Clinical Research
Tujunga, California
Medvin Clinical Research
Whittier, California
Clinical Research of West Florida, Inc
Clearwater, Florida
Great Lakes Clinical Trials dba Flourish Research Chicago
Chicago, Illinois
Accurate Clinical Research, Inc
Lake Charles, Louisiana
Lynn Health Science Institute
Oklahoma City, Oklahoma
Altoona Center for Clinical Research
Duncansville, Pennsylvania
Accurate Clinical Management, LLC
Baytown, Texas
Precision Comprehensive Clinical Research Solutions
Colleyville, Texas
Accurate Clinical Research, Inc
Houston, Texas
Precision Comprehensive Clinical Research Solutions
Irving, Texas
Southwest Rheumatology Research
Mesquite, Texas
Clinical Trials of Texas LLC, dba Flourish Research
San Antonio, Texas
DM Clinical Research
Tomball, Texas
Tidewater Clinical Research, LLC/ Virginia Rheumatology Clinic
Virginia Beach, Virginia
ARENSIA Exploratory Medicine, LLC
Tbilisi, Georgia
Universitatsklinikum Koln
Cologne, Germany
Krakenhaus Porz am Rhein
Cologne, Germany
Hamburger Rheuma Forschungszentrum II
Hamburg, Germany
Klinikum der Universitat Munchen
München, Germany
Republican Clinical Hospital "Timofei Mosneaga," Arensia EM
Chisinau, Moldova
Clinicmed Daniluk
Bialystok, Poland
FutureMeds Gydinia
Gdynia, Poland
FutureMeds Lodz
Lodz, Poland
MICS Centrum Medyczne Torun
Torun, Poland
FutureMeds Targowek
Warszawa Targówek, Poland
FutureMeds Wroclaw
Wroclaw, Poland
Complejo Hospitalario Universitario A Coruna
A Coruña, Spain
Hospital del Mar
Barcelona, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
Hospital Universitari Parc Tauli
Sabadell, Spain
Hospital Quironsalud Infanta Luisa
Seville, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.